Cerenome Reports Interim ReSPECT-LM Data: No Dose-Limiting Toxicity in First 10 Patients
CNSY has more than doubled off its 52-week low of $0.429 on elevated volume (10× avg).
Summary
Interim ReSPECT-LM data in the first 10 patients showed no dose-limiting toxicities and consistent repeat-dose radiation delivery, with no documented leptomeningeal progression at three or six months among evaluable patients. The findings are preliminary and descriptive, and the company is targeting a randomized Phase 2 study in 2027.
Key Events · Product Development and Regulatory · CNSY
-
Repeat Dosing Clears Safety Hurdle
No dose-limiting toxicities or adverse events leading to discontinuation occurred in the first 10 patients; the only serious adverse event, shortness of breath in one subject, was deemed unrelated to treatment.
-
Cumulative Activity Exceeds Prior Single Dose
One patient received three 26.4 mCi doses for 79.2 mCi total, above the 75 mCi highest single administration in the prior single-dose ReSPECT-LM study; that patient's estimated cumulative LM compartment absorbed dose was 207 Gy.
-
Consistent Delivery, Low Marrow Exposure
Absorbed dose per mCi varied by a median of 8% within patients across repeat administrations, and median blood-derived marrow absorbed dose was 0.023 Gy per administration (range 0.010-0.41 Gy).
-
Early Disease Control Signal
No LM progression was documented at the three- and six-month landmarks (0/5 evaluable at each); 1 of 4 evaluable patients progressed by nine months. Three patients with detectable baseline CSF tumor cells later had zero tumor cells/mL, two of them still at zero 9.2 and 2.3 months after the first dose.
Analysis · CNSY · Life Sciences
Cerenome's lead therapeutic asset has cleared its first repeat-dosing hurdle. In 10 patients who received multiple intraventricular REYOBIQ doses, there were no dose-limiting toxicities and no discontinuations, and one patient absorbed 79.2 mCi cumulative—above the 75 mCi highest single dose in the earlier study. Radiation delivery was reproducible, with a median 8% within-patient variation, and marrow exposure stayed low at a median 0.023 Gy per administration, the practical gate for escalating dose. The efficacy read is thin and descriptive—0/5 evaluable patients progressed at three and six months, 1 of 4 by nine months, with no PFS or OS claim—but it is directionally consistent with prior Phase 1 data. This matters because the company reported a going-concern warning and held only $879 thousand of cash at Q3, so clinical momentum is the main lever for financing the targeted 2027 randomized Phase 2 study.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNSY was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.43 to $18.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.